THE #1 PRESCRIBED HAE PREVENTIVE TREATMENT* – APPROVED IN PATIENTS AS YOUNG AS 2 YEARS OF AGE. OVER 5 YEARS OF PATIENT EXPERIENCE AND 3250+ PATIENTS PRESCRIBED SINCE 2018.1†

US-LANA-1731v1.0 12/22
Site search icon.
Mobile navigation icon.

TAKHZYRO (lanadelumab-flyo) is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in patients ≥2 years of age.

TAKHZYRO (lanadelumab-flyo) is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in patients ≥2 years of age.

This is my TAKHZYRO experience THIS IS MY TAKHZYRO Imagine what the #1 PRESCRIBED HAE preventive treatment* can mean for your patients Dennis
Real TAKHZYRO patient

TAKHZYRO is clinically proven to help prevent HAE attacks, and patients experienced long-term freedom from attacks for an average of 14.8 months.1,2

  • Evaluated in a 6.5-month study and a 2.5-year open-label extension (OLE) study
  • Mean duration of the attack-free period in the OLE study was 14.8 (SD=12.4) months (N=209)
Dennis
Real TAKHZYRO patient

* Based on total patients on HAE preventive treatments according to US third-party industry healthcare data.

The number of patients prescribed TAKHZYRO is based on third-party US specialty pharmacy data.

*Based on total patients on HAE preventive treatments according to US third-party industry healthcare data.
†Based on third-party US specialty pharmacy data.

Rediscover effective prevention

The safety and efficacy of TAKHZYRO (lanadelumab-flyo) were assessed in a 6.5 months pivotal trial of 125 HAE patients ≥12 years of age. The primary efficacy endpoint was the rate of investigator-confirmed attacks during the treatment period compared to placebo.1,3

Significant reduction in mean attack rate vs placebo at 6.5 months in the HELP study1,3

87%

REDUCTION
IN ATTACKS

vs placebo (Adjusted P<0.001)

  • TAKHZYRO 300 mg every 4 weeks resulted in a 73% reduction in attacks vs placebo (Adjusted P<0.001)
  • Mean monthly attack rate at baseline (during the run-in period): 3.52 for TAKHZYRO every 2 weeks (n=27); 3.71 for TAKHZYRO every 4 weeks (n=29); 4.02 for placebo (n=41)3
  • Mean monthly attack rate (during treatment): 0.26 for TAKHZYRO every 2 weeks; 0.53 for TAKHZYRO every 4 weeks; 1.97 for placebo1

All data presented are for TAKHZYRO 300 mg every 2 weeks unless otherwise indicated.1

Mean monthly attack rate: number of attacks/4 weeks.1

§Adjusted P-values for multiple testing.1

HELP study: A multicenter, double-blind, parallel group, placebo-controlled clinical study assessed the efficacy and safety of TAKHZYRO in 125 HAE Type I/II patients (≥12 years of age) for 6.5 months. Patients were treated with TAKHZYRO 150 mg q4wks, TAKHZYRO 300 mg q2wks, TAKHZYRO 300 mg q4wks, or placebo. Primary endpoint: rate of investigator-confirmed attacks during the treatment.1,3

STUDIED IN OVER
200
ADULT AND ADOLESCENT
PATIENTS ACROSS 3 STUDIES1,2
STUDIED FOR UP TO
2.5
YEARS IN THE HELP OPEN-LABEL EXTENSION STUDY FOR ADULT AND ADOLESCENT PATIENTS2
PRESCRIBED TO OVER
3250
PATIENTS SINCE 2018

Based on third-party US specialty pharmacy data.

explore takhzyro efficacy

Consistent safety results across all 3 studies1,2,4

The safety profile was consistent across 3 studies: a pivotal study of patients ≥12 plus an open-label extension study, and a pivotal study of patients 2 to <12. No new adverse events were observed in the pediatric population (2 to <12).1,2,4

EXPLORE SAFETY PROFILE

Freedom from daily dosing

  • 2 to <6 years of age: every-4-weeks dosing1
  • 6 to <12 years of age: every-2-weeks dosing1
    • 6 to <12 years of age: every-4-weeks dosing if patient is well-controlled (eg, attack free) for more than 6 months1
  • ≥12 years of age: every-2-weeks dosing1
    • ≥12 years of age: every-4-weeks dosing if patient is well-controlled (eg, attack free) for more than 6 months1

REVIEW DOSING & ADMINISTRATION

Help patients set proper treatment expectations

Setting expectations

Find tips for helping patients stay on track with TAKHZYRO

KEEPING PATIENTS ON TRACK

Get emails with updated
resources and information
about TAKHZYRO

Sign up

Join HAE events to
hear from experts and
engage with the community

Register now
OnePath® logo.

Providing product support to patients with HAE for over 12 years

Remind patients that OnePath® helps people who have been prescribed TAKHZYRO per the approved indication get access to their medication.

References: 1. Takhzyro. Prescribing information. Dyax Corp; 2023. 2. Banerji A, Bernstein JA, Johnston DT, et al; HELP OLE Investigators. Allergy. 2022;77(3):979-990. doi:10.1111/all.15011 3. Banerji A, Riedl MA, Bernstein JA, et al. JAMA. 2018;320(20):2108-2121. doi:10.1001/jama.2018.16773 4. Maurer M, Magerl M, Betschel S, et al. Allergy. 2022;77(7):1961-1990. doi:10.1111/all.15214